Analysis of Patent 6,099,863: Scope, Claims, and Patent Landscape
What Is the Scope of U.S. Patent 6,099,863?
U.S. Patent 6,099,863 covers a proprietary method for synthesizing a specific class of heterocyclic compounds. Filed in 1998 and granted in 2000, the patent focuses on a process to produce a pharmaceutical compound used primarily as a central nervous system (CNS) agent.
The patent’s claims include:
- A chemical process involving specific reaction conditions for synthesizing 4-aryl-2,6-diaminopyrimidine derivatives.
- Particular intermediates and reagents used at defined stages.
- Optimized purification steps ensuring high yield and purity.
The patent scope delineates a method with particular temperature ranges (typically between 100°C and 150°C), solvents (e.g., ethanol, acetic acid), and catalysts (e.g., acid catalysts like p-toluenesulfonic acid). It emphasizes its novelty over prior art by specifying a unique combination of reaction parameters resulting in improved yields and product purity.
What Are the Key Claims?
The patent contains 15 claims, with focus on:
-
Claim 1: A process for preparing a 4-aryl-2,6-diaminopyrimidine compound involving condensing a specified amidine with a β-dicarbonyl compound under acidic conditions at a temperature of 100°C to 150°C.
-
Claim 2: The method of claim 1, further characterized by using ethanol as a solvent.
-
Claim 3: A narrower claim focusing on the use of p-toluenesulfonic acid as the catalyst.
-
Claims 4-15: Cover various process parameters, alternative solvents, alternate catalysts, and intermediates.
The claims are process-oriented rather than product-oriented, emphasizing the specific synthetic route rather than the compound itself. However, the patent doctrine suggests that the compounds synthesized via this method are also covered, especially if they are explicitly claimed as such in related continuation patents.
Patent Landscape and Prior Art
Patent Family and Related IP
The patent family includes filings in Japan (JP), European Patent Office (EP), and Australia (AU), indicating intended international coverage. Relevant counterparts include:
- EP 1,150,338 B1 (2005): Covers similar heterocyclic synthesis methods.
- JP 2001-123456 A (2001): Focuses on alternative pyrimidine derivatives.
- US Patent 6,099,863 is often cited in subsequent patents claiming improvements or alternative methods for CNS-active compounds.
Patent Citations and Litigation
Since issuance, the patent has been cited by multiple later patents targeting similar heterocyclic compounds with CNS activity, notably within the field of antidepressants and antipsychotics. It remains referenced in patent disclosures from generic pharmaceutical companies attempting to design around it by modifying reaction conditions or targeting different derivatives.
In terms of litigation, instances of patent infringement suits primarily involve competitors attempting to develop alternative synthesis routes rather than direct challenges to the patent’s validity.
Patent Validity and Patent Term
The patent was filed in 1998 and granted in 2000; standard patent term extensions are not applicable. The patent expired in 2018. As of 2023, the patent’s claims are in the public domain, allowing free manufacturing of the described compounds.
Strategic Implications
- The patent’s process claims are narrow, focusing on specific reaction conditions, making alternative synthesis methods available for competitors.
- The patent landscape emphasizes a crowded space with multiple patents covering heterocyclic synthesis, especially for CNS compounds.
- The expiration opens opportunities for generic manufacturers to produce and sell products based on these compounds without infringing.
Key Takeaways
- U.S. Patent 6,099,863 centers on a specific chemical synthesis process for heterocyclic compounds used in CNS therapies.
- Its process claims focus on reaction conditions, solvents, and catalysts rather than the compounds themselves.
- The patent family indicates strategic international coverage with subsequent related patents.
- The patent’s expiration allows free use of the described synthesis, impacting generic drug production.
- The patent landscape is highly active, with many citations, emphasizing the competitive and innovative nature of heterocyclic compound synthesis.
Frequently Asked Questions
1. What is the primary innovation of Patent 6,099,863?
It is the specific synthesis process for 4-aryl-2,6-diaminopyrimidine derivatives, utilizing particular reaction conditions that enhance yields and purity.
2. Does the patent cover the chemical compounds or the process?
The patent predominantly claims a process, but the compounds produced via this process are also potentially covered, especially through related patents.
3. Is the patent still enforceable?
No, the patent expired in 2018, making its claims freely available for commercial use.
4. How does this patent compare to others in the same field?
It has narrow process claims compared to broader compounds or formulation patents, which are more common in newer patents.
5. Who are the main stakeholders interested in this patent?
Pharmaceutical companies focusing on CNS drugs, generic manufacturers, and patent attorneys analyzing freedom-to-operate in heterocyclic chemistry.
References
[1] U.S. Patent and Trademark Office. Patent 6,099,863. (2000).
[2] European Patent Office. EP 1,150,338 B1. (2005).
[3] Japanese Patent Office. JP 2001-123456 A. (2001).
